ToRsemide for pOstpartum HYpertension

• Status: Completed
• Trial end date: 2017-09-09
• Target enrollment: 0
• Participant gender: Female

Summary

Currently there is no intervention to prevent persistent postpartum hypertension in preeclamptic women. Physiologically, the use of a pharmacokinetically predictable loop-diuretic is a reasonable intervention to increase elimination of extra fluid accumulated secondary to preeclampsia.The purpose of this study is to assess if Torsemide reduces the incidence of persistent postpartum hypertension in preeclamptic women.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: The University of Texas Health Science Center, Houston
• Treatments: Torsemide

Criteria

Inclusion Criteria:

• Postpartum women at ≥ 18 years of age

• Antepartum/intrapartum or within 24 hours postpartum diagnosis of either:

• Preeclampsia

• Preeclampsia with severe features

• Preeclampsia superimposed to chronic hypertension

Exclusion Criteria:

• Chronic hypertension without superimposed preeclampsia

• Gestational hypertension

• Urine output < 30 cc/h at time of randomization

• Heart failure or pulmonary edema

• Hypersensitivity to Torsemide or sulfonylureas

• Hypokalemia (serum potassium < 3 mEq/L)

• Preexisting diuretic use within 24 hours prior to randomization